Kairos Ventures portfolio company Axial Biotherapeutics announced the appointment of Dr. Gregory T. Bates as Senior Vice President of...

Read more
By: Kairos Ventures On: November 6, 2017 In: Portfolio News, Provivi

We are pleased to announce that our portfolio company Provivi, Inc. closed on the first $21 million of a...

Read more
By: Kairos Ventures On: November 1, 2017 In: Portfolio News, Symbiotix

We are pleased to announce that Symbiotix Biotherapies, Inc. is the latest company to join the Kairos portfolio. Founded in...

Read more
By: Kairos Ventures On: October 8, 2017 In: MixComm, Portfolio News

We are delighted to announce that MixComm Inc. is the latest company to join the Kairos portfolio. MixComm Inc....

Read more

Founded in 2017 Opera Therapeutics is a biopharmaceutical company that is developing next-generation treatments for ocular and neurological diseases.

Read more
By: Kairos Ventures On: September 29, 2017 In: Auspion, Portfolio News

We are thrilled to announce that Auspion Inc. has joined the Kairos Portfolio. Auspion, Inc. is a wireless communications...

Read more

We're excited to share that our portfolio company, Axial Biotherapeutics, has been selected as one of FierceBiotech's Fierce 15...

Read more

We are delighted to announce that Chimera Bioengineering is the latest company to join the Kairos portfolio. Founded in...

Read more

We are pleased to announce that Transient Plasma Systems (TPS) is the latest company to join the Kairos portfolio....

Read more
By: Kairos Ventures On: August 10, 2017 In: Delpor, Portfolio News

Healthline recently published an article on the importance of implantable drugs, including Delpor’s implant devices. The first half of...

Read more